Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CNS
MCID: CNT035
MIFTS: 49

Central Nervous System Disease (CNS)

Categories: Blood diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Central Nervous System Disease

About this section

MalaCards integrated aliases for Central Nervous System Disease:

Name: Central Nervous System Disease 11 14 16 75
Central Nervous System Diseases 43
Cns Diseases 53
Cns Disorder 71
Cns 47

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:331
MeSH 43 D002493
NCIt 49 C2934
SNOMED-CT 68 267144009
ICD10 31 G96 G96.8 G96.9
UMLS 71 C0007682
Sources

Summaries for Central Nervous System Disease

About this section

Disease Ontology: 11 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary: Central Nervous System Disease, also known as central nervous system diseases, is related to central nervous system cancer and nervous system disease, and has symptoms including headache, hemiplegia and hyperexplexia. An important gene associated with Central Nervous System Disease is SOX2-OT (SOX2 Overlapping Transcript), and among its related pathways/superpathways are Signal Transduction and Neuroinflammation and glutamatergic signaling. The drugs Flupentixol and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone marrow.

Wikipedia: 75 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...
Sources

Related Diseases for Central Nervous System Disease

About this section

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease Infectious Disease of the Nervous System

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2236)
# Related Disease Score Top Affiliating Genes
1 central nervous system cancer 33.1 SERPINA3 MIR9-1 MIR199A1 H2AC18 CCR6
2 nervous system disease 33.0 TBK1 SERPINA3 MOG MMP9 MIR9-1 MIR199A1
3 demyelinating disease 32.8 SERPINA3 MOG MMP9 MIR9-1 MBP MAPT
4 meningoencephalitis 32.8 SERPINA3 MOG MBP CXCR3 CCR6 BDNF
5 neuromyelitis optica 32.6 MOG MBP GFAP
6 gerstmann-straussler disease 32.4 SERPINA3 MAPT APP
7 fetal alcohol syndrome 32.2 MIR9-1 H2AC18 BDNF
8 spinal cord injury 31.9 MMP9 GFAP BDNF
9 immune deficiency disease 31.8 TBK1 SERPINA3 MIR9-1 MIR199A1 MBP H2AC18
10 viral infectious disease 31.7 TBK1 SERPINA3 MIR199A1 H2AC18 CXCR3 CCR6
11 high grade glioma 31.6 MMP9 MIR9-1 MIR199A1 H2AC18 H19 GFAP
12 leukemia, acute lymphoblastic 31.5 MIR9-1 MIR199A1 H2AC18 CXCR3 CCR6
13 neuritis 31.5 MOG MMP9 MBP MAPT GFAP BDNF
14 stroke, ischemic 31.5 SERPINA3 MMP9 MIR9-1 MBP MAPT GFAP
15 optic neuritis 31.5 MOG MBP GFAP CXCR3 BDNF
16 leukemia, acute myeloid 31.5 SERPINA3 MMP9 MIR9-1 MIR199A1 H2AC18 CCR6
17 dementia 31.4 TBK1 SERPINA3 MAPT GFAP BDNF APP
18 amyotrophic lateral sclerosis 1 31.4 TBK1 SERPINA3 MOG MMP9 MIR9-1 MIR199A1
19 prion disease 31.4 SERPINA3 MIR9-1 MAPT APP
20 viral encephalitis 31.3 SERPINA3 MOG MBP CCR6
21 attention deficit-hyperactivity disorder 31.3 SERPINA3 MAPT H2AC18 GRM5 GRM2 BDNF
22 transverse myelitis 31.3 MOG MBP CCR6
23 alcohol use disorder 31.3 SERPINA3 MIR199A1 H2AC18 CCR6 BDNF
24 spinal cord disease 31.3 SERPINA3 MOG MIR9-1 MIR199A1 MBP H2AC18
25 autoimmune disease 31.3 MOG MMP9 MBP CXCR3 CCR6
26 optic nerve disease 31.3 SERPINA3 MOG MBP GFAP CCR6 BDNF
27 schizophrenia 31.3 SERPINA3 MOG MMP9 MIR9-1 MBP MAPT
28 myelitis 31.2 MOG MMP9 MBP CCR6
29 cerebral artery occlusion 31.2 MMP9 GFAP BDNF
30 bipolar disorder 31.2 MAPT GRM5 GRM2 GFAP BDNF APP
31 mood disorder 31.2 SERPINA3 MIR9-1 H2AC18 BDNF
32 multiple sclerosis 31.2 MOG MMP9 MBP GFAP CXCR3 CCR6
33 alcohol dependence 31.2 SERPINA3 MAPT H2AC18 GRM5 BDNF
34 connective tissue disease 31.2 SERPINA3 MMP9 MIR9-1 MIR199A1 H2AC18 CCR6
35 parkinson disease, late-onset 31.2 SERPINA3 MIR9-1 MBP MAPT H2AC18 H19
36 migraine with or without aura 1 31.2 SERPINA3 MMP9 H2AC18 GRM5 GRM2 GFAP
37 body mass index quantitative trait locus 11 31.1 SERPINA3 MMP9 MIR9-1 MIR199A1 H2AC18 H19
38 movement disease 31.1 SERPINA3 MIR9-1 MAPT H2AC18 GFAP BDNF
39 hydrocephalus 31.1 SERPINA3 MBP MAPT GFAP BDNF APP
40 allergic disease 31.1 SERPINA3 H2AC18 CCR6 BDNF
41 psychotic disorder 31.1 SERPINA3 MIR9-1 H2AC18 GRM5 GRM2 BDNF
42 frontotemporal dementia 31.1 TBK1 SERPINA3 MMP9 MIR9-1 MAPT H2AC18
43 aphasia 31.1 TBK1 MAPT BDNF APP
44 lysosomal storage disease 31.1 SERPINA3 MIR9-1 MIR199A1 H2AC18 CCR6
45 dementia, lewy body 31.1 SERPINA3 MIR9-1 MAPT H2AC18 GFAP BDNF
46 secondary progressive multiple sclerosis 31.1 SERPINA3 MOG MBP CCR6
47 anaplastic astrocytoma 31.1 SERPINA3 MMP9 H2AC18 GFAP
48 status epilepticus 31.1 GRM5 GRM2 GFAP BDNF
49 myeloma, multiple 31.1 MIR9-1 MIR199A1 H2AC18 H19 CCR6 BDNF
50 acute disseminated encephalomyelitis 31.1 MOG MBP CCR6

Graphical network of the top 20 diseases related to Central Nervous System Disease:



Diseases related to Central Nervous System Disease
Sources

Symptoms & Phenotypes for Central Nervous System Disease

About this section

UMLS symptoms related to Central Nervous System Disease:


headache; hemiplegia; hyperexplexia
Sources

Drugs & Therapeutics for Central Nervous System Disease

About this section

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Flupentixol Approved, Investigational, Withdrawn Phase 4 2709-56-0 25137855 5281881 17012
2
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
3
Clozapine Approved Phase 4 5786-21-0 2818 135398737
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Zidovudine Approved Phase 4 30516-87-1 35370
8
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
9
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
10
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
11 Anticoagulants Phase 4
12 Analgesics Phase 4
13 Hypnotics and Sedatives Phase 4
14 Psychotropic Drugs Phase 4
15 Dopamine Antagonists Phase 4
16 Antipsychotic Agents Phase 4
17 Flupenthixol decanoate Phase 4
18 Whey Protein Phase 4
19 Soy Bean Phase 4
20 Anti-Retroviral Agents Phase 4
21 Lamivudine, zidovudine drug combination Phase 4
22 Antimetabolites Phase 4
23 Anti-HIV Agents Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Reverse Transcriptase Inhibitors Phase 4
26 Neuroprotective Agents Phase 4
27 Protective Agents Phase 4
28 Platelet Aggregation Inhibitors Phase 4
29 3-n-butylphthalide Phase 4
30 Bifidobacterium Phase 4
31 Acidophilus Phase 4
32 Sulfalene Phase 4
33 Adrenergic alpha-Agonists Phase 4
34 Adrenergic Agonists Phase 4
35 Adrenergic Agents Phase 4
36 Analgesics, Non-Narcotic Phase 4
37
Ezogabine Approved, Investigational Phase 3 150812-12-7 121892
38 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 3
39 Chelating Agents Phase 3
40 Anticonvulsants Phase 3
41
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
42
Entacapone Approved, Investigational Phase 2 130929-57-6 5281081
43
Carbidopa Approved Phase 2 28860-95-9 34359 38101
44
Pramipexole Approved, Investigational Phase 2 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
45
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
46
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
47
Rotigotine Approved Phase 2 99755-59-6, 92206-54-7 57537 59227
48
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
49
Ceftriaxone Approved Phase 2 73384-59-5 5479530
50
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Unknown status NCT02684825 Phase 4
2 Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients Completed NCT04898270 Phase 4 Flupentixol;Multi-acting receptor-targeted antipsychotics (MARTAs)
3 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function Completed NCT01662414 Phase 4
4 Impact of Prophylactic Use of Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Pilot Randomized Controlled Trial Completed NCT04494828 Phase 4 Dexmedetomidine;Normal saline group
5 Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial) Completed NCT01445639 Phase 4 Dexmedetomidine;Normal saline
6 Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China Completed NCT01340950 Phase 4 zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz
7 A Real-world Study on the Effectiveness and Safety of Butylphthalide in the Treatment of Ischemic Stroke. Recruiting NCT05068349 Phase 4 Butylphthalide
8 Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study Recruiting NCT04871464 Phase 4 Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
9 Dexmedetomidine for Prevention of Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Multicenter Randomized Controlled Trial Not yet recruiting NCT04399343 Phase 4 Dexmedetomidine;Normal saline
10 A Multicenter, Randomized, Double-blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS) Completed NCT00709852 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875);Gadoteridol (ProHance)
11 A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients Completed NCT00395460 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875);Magnevist
12 A Multicenter, Open-label, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS). Completed NCT00623467 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875)
13 Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions. Completed NCT01211873 Phase 3 Dotarem (gadoterate meglumine);Magnevist (gadopentetate dimeglumine)
14 A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy Recruiting NCT04639310 Phase 3 XEN496;Placebo
15 An Open-Label Extension of the Study XEN496 in Children With KCNQ2 Developmental and Epileptic Encephalopathy Recruiting NCT04912856 Phase 3 XEN496;Placebo
16 Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease Recruiting NCT05508789 Phase 3 Donanemab;Placebo
17 A Phase III Multi-Center Open Label Study to Evaluate Safety and Efficacy of MultiHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Terminated NCT00323310 Phase 3 gadobenate dimeglumine
18 A Randomized, 24 Week Parallel-group Placebo-controlled (Phase 2) Pilot-study of High Dose Omega 3 (DHA) in People at Risk for Dementia Unknown status NCT03926351 Phase 2
19 Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease Completed NCT00004642 Phase 1, Phase 2 SDZ MSL-109
20 Long Term Effects of Soft Splints on Stroke Patients and Patients With Disorders of Consciousness Completed NCT03008486 Phase 2
21 A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175) Completed NCT00537017 Phase 2 Preladenant;L-dopa;Other Parkinson's Disease treatments
22 A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias Completed NCT00406029 Phase 2 Preladenant;Placebo;L-dopa;Other Parkinson's Disease treatments
23 Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS Completed NCT03127514 Phase 2 AMX0035
24 A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease Completed NCT01073228 Phase 2 EVP-6124;Placebo
25 A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy Completed NCT00968851 Phase 2 EVP-6124;Placebo
26 FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke Completed NCT03448159 Phase 2 Fluoxetine Hydrochloride
27 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age Recruiting NCT05590884 Phase 2 Gadopiclenol
28 An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD That Have Completed a Phase 2 Study With XPro1595 Recruiting NCT05522387 Phase 2 XPro1595
29 A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XProâ„¢ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation. Recruiting NCT05318976 Phase 2 XPro1595;Placebo
30 Locomotor Training With Testosterone to Promote Bone and Muscle Health Recruiting NCT04460872 Phase 2 Testosterone Enanthate
31 An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer Recruiting NCT05386108 Phase 1, Phase 2 Abemaciclib;Elacestrant
32 Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments Active, not recruiting NCT04640077 Phase 2 donanemab
33 A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease Active, not recruiting NCT04445831 Phase 1, Phase 2
34 Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients With Behavioral FTD Active, not recruiting NCT04937452 Phase 2 Rotigotine 4Mg/24Hrs Patch;Rotigotine 6Mg/24Hrs Patch;Placebo
35 A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation Not yet recruiting NCT05321498 Phase 2 XPro1595;Placebo
36 A Randomized, Blank-controlled, Open Label Study of the Safety and Efficacy of Propranolol in Reducing Stroke Associated Pneumonia and Urinary Tract Infection Not yet recruiting NCT05375240 Phase 2 Propranolol;Ceftriaxone
37 A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease Suspended NCT04912115 Phase 2 Ketamine;Midazolam
38 Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI Terminated NCT02248701 Phase 2 Testosterone Enanthate;Finasteride;Placebo injection;Placebo pill
39 A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases Terminated NCT00496379 Phase 2 ZK219477
40 A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease) Withdrawn NCT01610765 Phase 1, Phase 2 Novel Antiviral Drug;Placebo
41 TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases Withdrawn NCT04512261 Phase 1, Phase 2 Tucatinib;Pembrolizumab;Trastuzumab
42 An Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell("HYNR-CS-Allo Inj") Treatment in Amyotrophic Lateral Sclerosis(ALS) Completed NCT01758510 Phase 1
43 A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT00766363 Phase 1 EVP-6124 (0.1 mg/day);EVP-6124 (0.3 mg/day);EVP-6124 (1.0 mg/day);Comparator: Placebo;Donepezil;Rivastigmine
44 Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas Completed NCT00805376 Phase 1 DNX-2401
45 A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases Completed NCT00649207 Phase 1 ABT-888
46 An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa Completed NCT03065192 Phase 1 VY-AADC01
47 A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of D797 on Pharmacokinetics of D324 in Healthy Volunteers Completed NCT03569579 Phase 1 Memantine Tab. 10mg;Memantine Tab. 10mg + Donepezil Tab. 10mg
48 A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics Completed NCT01556763 Phase 1 EVP-6124 (0.3 mg/day);EVP-6124 (1.0 mg/day);Placebo;Antipsychotic therapy
49 A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
50 Blood-Brain Barrier Penetration of Therapeutic Agents in Human - an Exploratory Repeated Dose Pharmacokinetic Study in Patients With Idiopathic Normal Pressure Hydrocephalus Treated With Cerebroventricular Shunting Completed NCT04571996 Phase 1 ODM-104;Paracetamol

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Sources

Genetic Tests for Central Nervous System Disease

About this section
Sources

Anatomical Context for Central Nervous System Disease

About this section

Organs/tissues related to Central Nervous System Disease:

MalaCards : Spinal Cord, Brain, Bone Marrow, Prefrontal Cortex, Cortex, Breast, Bone
Sources

Publications for Central Nervous System Disease

About this section

Articles related to Central Nervous System Disease:

(show top 50) (show all 4192)
# Title Authors PMID Year
1
Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter. 53 62
20520825 2010
2
Different proteolipid protein mutants exhibit unique metabolic defects. 53 62
19663806 2009
3
The role of death receptors in neural injury. 53 62
19273087 2009
4
Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. 53 62
17470817 2007
5
Sequence variation in the CC-chemokine ligand 2 promoter of pigtailed macaques is not associated with the incidence or severity of neuropathology in a simian immunodeficiency virus model of human immunodeficiency virus central nervous system disease. 53 62
17162657 2006
6
3-Aza-6,8-dioxabicyclo[3.2.1]octanes as new enantiopure heteroatom-rich tropane-like ligands of human dopamine transporter. 53 62
16678430 2006
7
Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. 53 62
16475952 2006
8
Prediction of neuropathology in mucopolysaccharidosis I patients. 53 62
15639191 2005
9
Oncostatin M: a pleiotropic cytokine in the central nervous system. 53 62
15450253 2004
10
Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity. 53 62
14977565 2004
11
Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress. 53 62
15105257 2004
12
Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. 53 62
14872175 2004
13
The role of BDNF in epilepsy and other diseases of the mature nervous system. 53 62
15250584 2004
14
Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease. 53 62
12477824 2003
15
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. 53 62
12021361 2002
16
The role of tau in Alzheimer's disease. 53 62
12168561 2002
17
Marmoset fine B cell and T cell epitope specificities mapped onto a homology model of the extracellular domain of human myelin oligodendrocyte glycoprotein. 53 62
11895369 2002
18
Accumulation of beta-amyloid precursor protein in axons correlates with CNS expression of SIV gp41. 53 62
11829347 2002
19
Intraoperative values of S-100 protein, myelin basic protein, lactate, and albumin in the CSF and serum of neurosurgical patients. 53 62
11606682 2001
20
Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. 53 62
11574916 2001
21
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination. 62
36411077 2023
22
Muse cells decrease the neuroinflammatory response by modulating the proportion of M1 and M2 microglia in vitro. 62
35799545 2023
23
Uncariphyllin A-J, indole alkaloids from Uncaria rhynchophylla as antagonists of dopamine D2 and Mu opioid receptors. 62
36375349 2023
24
The AMPK-SIRT1-FoxO1-NF-κB signaling pathway participates in hesperetin-mediated neuroprotective effects against traumatic brain injury via the NLRP3 inflammasome. 62
35786120 2022
25
Variations in Aspects of Neural Precursor Cell Neurogenesis in a Human Model of HSV-1 Infection. 62
35384798 2022
26
Molecular Mechanism of the Protective Effects of M2 Microglia on Neurons: A Review Focused on Exosomes and Secretory Proteins. 62
36222957 2022
27
Role of 3D Printing in the Development of Biodegradable Implants for Central Nervous System Drug Delivery. 62
36154128 2022
28
Endothelial cell activation by interleukin-1 and extracellular matrix laminin-10 occurs via the YAP signalling pathway. 62
36327619 2022
29
Applications of focused ultrasound-mediated blood-brain barrier opening. 62
36272635 2022
30
The therapeutic potential of bone marrow-derived macrophages in neurological diseases. 62
36066198 2022
31
Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies. 62
36252748 2022
32
Intestinal Flora Affect Alzheimer's Disease by Regulating Endogenous Hormones. 62
36309938 2022
33
Outcomes of 434 dogs with non-steroidal anti-inflammatory drug toxicosis treated with fluid therapy, lipid emulsion, or therapeutic plasma exchange. 62
36453531 2022
34
Chitosan-modified hollow manganese dioxide nanoparticles loaded with resveratrol for the treatment of spinal cord injury. 62
35903814 2022
35
Fruquintinib/HMPL-013 ameliorates cognitive impairments and pathology in a mouse model of cerebral amyloid angiopathy (CAA). 62
36470443 2022
36
Pharmacological effects of salidroside on central nervous system diseases. 62
36228376 2022
37
Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases. 62
35960392 2022
38
Progress and Challenges in Bacterial Meningitis: A Review. 62
36472590 2022
39
Diagnostics and theranostics of central nervous system diseases based on aggregation-induced emission luminogens. 62
36126555 2022
40
Effects of radiation exposure on brain health: a state of the art and new challenges. 62
36308656 2022
41
Role of Necroptosis in Central Nervous System Diseases. 62
36373337 2022
42
Inflammatory bowel disease: A potential pathogenic factor of Alzheimer's disease. 62
35908596 2022
43
Safety of Remdesivir in 20 Children with COVID-19-Case Series- 62
36216548 2022
44
Nano-integrated cascade antioxidases opsonized by albumin bypass the blood-brain barrier for treatment of ischemia-reperfusion injury. 62
36341569 2022
45
Depletion of regulatory T cells exacerbates inflammatory responses after chronic cerebral hypoperfusion in mice. 62
36302461 2022
46
Lipoxygenase Metabolism: Critical Pathways in Microglia-mediated Neuroinflammation and Neurodevelopmental Disorders. 62
35674930 2022
47
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. 62
36243020 2022
48
Health-Related Indicators Measured Using Earable Devices: Systematic Review. 62
36239201 2022
49
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. 62
36379126 2022
50
Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus. 62
36431345 2022
Sources

Variations for Central Nervous System Disease

About this section
Sources

Expression for Central Nervous System Disease

About this section
Search GEO for disease gene expression data for Central Nervous System Disease.
Sources

Pathways for Central Nervous System Disease

About this section

Pathways related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.11 TBK1 MMP9 H2AC18 GRM5 GRM2 GFAP
2
Neuroinflammation and glutamatergic signaling 74
11.77 GRM5 GRM2 GFAP BDNF
3
Fragile X syndrome 74
Show member pathways
 11.65 MMP9 GRM5 BDNF APP
4
Neuroscience 3
11.63 MBP MAPT GRM5 GRM2 GFAP APP
5
Spinal cord injury 74
11.52 MMP9 MBP GFAP BDNF
6
Neural Stem Cells and Lineage-specific Markers 65
11.48 MOG GFAP BDNF
7
Neurogenesis regulation in the olfactory epithelium 74
11.3 MAPT BDNF APP
Sources

GO Terms for Central Nervous System Disease

About this section

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 main axon GO:0044304 9.26 MAPT APP
2 astrocyte projection GO:0097449 9.17 GRM5 GRM2 GFAP APP

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.7 MIR199A1 CXCR3 CCR6 CCR1
2 negative regulation of gene expression GO:0010629 9.32 TBK1 MIR9-1 MIR199A1 MAPT CCR1 APP
3 positive regulation of receptor binding GO:1900122 9.26 MMP9 BDNF

Molecular functions related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-C chemokine binding GO:0019957 9.63 CXCR3 CCR6 CCR1
2 C-C chemokine receptor activity GO:0016493 9.43 CXCR3 CCR6 CCR1
3 chemokine receptor activity GO:0004950 9.1 CXCR3 CCR6 CCR1
Sources

Sources for Central Nervous System Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....